<DOC>
	<DOCNO>NCT00193401</DOCNO>
	<brief_summary>In phase II trial , evaluate weekly schedule topotecan first-line treatment elderly and/or poor performance status patient extensive stage small cell lung cancer . Patients eligible trial consider poor candidate standard combination chemotherapy investigational regimen</brief_summary>
	<brief_title>Weekly Topotecan First-line Treatment Elderly Patients With Small Cell Lung Cancer</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : - Topotecan</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>To include study , must meet following criterion : Biopsyproven small cell lung cancer , extensive stage disease Age &gt; 65 year No previous chemotherapy radiation therapy . Measurable evaluable disease . Adequate bone marrow , liver kidney function . Must &gt; 4 week previous major surgery Must give write informed consent prior study entry . You participate study follow apply : Meningeal involvement Serious active infection Serious underlie medical condition Other active neoplasm Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>